Avalyn Pharma Inc.
corporate_fare Company Profile
Avalyn Pharma Inc. (NASDAQ:AVLN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for AVLN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-12, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for AVLN spans 10-Q, 8-K, SCHEDULE 13D, 4.
Recent high-impact activity:
- Avalyn Pharma Q2 2026: $413.5M Cash Funds Pipeline into 2029, Key Clinical Data Readouts in 2027
- Avalyn Q2 2026: $413.5M Cash, MIST Over-Enrolled, Topline Data in H2 2027
- Avalyn Finishes Enrollment for Phase 2b MIST Trial of AP01 in Pulmonary Fibrosis
- Q1 Net Loss of $26.9M, EPS $(21.83) Reported by Avalyn Pharma Post-IPO
- Avalyn Pharma Details Strong Post-IPO Cash Position and Extended Runway into 2029
Short Interest & Short Volume
9.56 days to coverFINRA reported short interest of 2,093,252 shares in AVLN as of the September 15, 2026 settlement, a 8.4% increase from the prior period — about 9.6 days to cover at its recent average daily volume. On October 2, 2026, 80.4% of AVLN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for AVLN, detected from its recent SEC filings · based on capital-structure filings through 2026-04-30.
Initial Public Offering Finalized · Substantial Capital Raised
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →